<DOC>
	<DOCNO>NCT01400425</DOCNO>
	<brief_summary>The study design evaluate whether florbetapir F 18 PET scan impact clinical thinking physician determine likely cause subject 's cognitive impairment .</brief_summary>
	<brief_title>Potential Florbetapir F 18 PET Inform Clinical Diagnosis Management Patients With Progressive Cognitive Decline</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Are one follow : 1 . Group A : Recently complete ( within past 18 month ) comprehensive clinical evaluation progressive cognitive decline . 2 . Group B : Currently evaluate progressive cognitive decline clinical laboratory test still plan . Have site enrol physician 1. less high confidence diagnosis subject relate cognitive decline time enrollment . The level confidence diagnosis rat physician less 85 % , interpreted physician estimate diagnosis correct le 85 % patient presentation subject ; 2. suspicion subject 's cognitive decline cause , least part , Alzheimer 's disease . The level suspicion rat physician least 15 % patient presentation subject would Alzheimer 's disease ; Can tolerate 10 minute PET scan . The Principal Investigator carefully assess subject use sound medical judgment determine whether subject tolerate PET scan procedure ; Have ability cooperate comply study procedure ; Have study partner willing accompany subject study visit ; Give inform consent study procedure ( If subject incapable give informed consent , subject 's designated decision maker may consent behalf subject subject must still confirm assent . This person may serve study partner well ) . Subject site enrol physician know result previous amyloid image scan . Are consider medically unstable ; Require additional laboratory test workup enrollment completion florbetapir F 18 PET scan ; Have clinically significant infectious disease , include Acquired Immunodeficiency Syndrome ( AIDS ) Human Immunodeficiency Virus ( HIV ) infection ; Are receive investigational medication , participate trial investigational medication within last 30 day ; Have ever participate experimental study amyloid target agent unless document subject receive placebo course trial ; Have radiopharmaceutical imaging treatment procedure within 7 day prior study image session ; Are females childbearing potential surgically sterile , refrain sexual activity use reliable method contraception . Females childbearing potential must pregnant ( negative serum βhCG time screen negative urine βhCG day image ) breast feed screen . Females must avoid become pregnant , must agree refrain sexual activity use reliable contraceptive method prescribe birth control intrauterine device ( IUD ) 24 hour follow administration florbetapir F 18 .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>